Compare Crispr Therapeutics AG (CRSP) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Southern Copper Corp — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while Southern Copper Corp trades at $209.75 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 34.4× Crispr Therapeutics AG's market cap, and Southern Copper Corp pays a 2.21% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Southern Copper Corp for 61 Days on average.
| CRSP | SCCO | |
|---|---|---|
Market Cap | $4.88B | $167.74B |
Volume | 2,861,747 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $219.70 |
52-Week Low | $44.34 | $120.02 |
Typical Hold Time | 77 Days | 61 Days |
Enterprise Value | $3.30B | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Southern Copper (SCCO) trades at $209.21, up 4.31% with strong earnings momentum, beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 35.87% net margins and 50.07% ROE. Recent news highlights the company's $10.2B Mexican project pipeline as a long-term growth driver while current sentiment remains mixed amid copper price volatility.
SCCO presents a valuation premium with P/E of 29.81 and P/S of 10.72, trading above analyst consensus target of $167.67. While operational excellence and project pipeline support upside potential, elevated valuation and bearish technicals suggest near-term caution. The stock faces headwinds from copper market volatility and competitive pressures in the materials sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
